Bangalore, May 07, 2026: Venus Remedies Limited (NSE: VENUSREM, BSE: 526953), among the world’s leading fixed-dosage injectable manufacturers, has secured marketing authorization from Argentina’s national regulatory authority for its antibiotic, Ceftriaxone. The approval marks a significant milestone in the company’s expansion across Latin America, strengthening its growing international portfolio and taking the total marketing authorizations (MAs) for Ceftriaxone to 39 globally. The development further reinforces Venus Remedies’ commitment to improving access to essential anti-infective therapies while supporting India’s growing role as a reliable supplier of high-quality injectable pharmaceuticals worldwide.
Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and CEO, Venus Medicine Research Centre, said, “The approval of Ceftriaxone in Argentina represents an important step in strengthening our presence in the Latin American region. Argentina is the fourth-largest pharmaceutical market in Latin America, valued at approximately USD7.3 billion in 2023, making it a strategically important market for high-quality critical care therapies. Ceftriaxone remains a cornerstone antibiotic in the management of several serious bacterial infections, including meningitis, respiratory tract infections, bloodstream infections, and surgical infections, making it a critical therapy in hospital and intensive care settings. This authorization aligns with our focus on delivering clinically relevant and widely accessible anti-infective therapies across global markets.”
The broader Latin American pharmaceutical market continues to demonstrate steady growth, reinforcing the region’s significance for India’s pharmaceutical exports and long-term healthcare partnerships. The overall Latin American pharmaceutical market is estimated at nearly US$91.85 billion in 2024, projected to reach US$ 172.71 billion by 2034, showing a healthy CAGR of 6.52% across the forecast years.
Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing this marketing authorization in Argentina is a strategically important milestone in our Latin America expansion journey. India exported approximately US$17.5 million worth of pharmaceutical products to Argentina in 2024, while Latin America and the Caribbean accounted for 6.69% of India’s total pharma exports in FY 2024–25. At Venus Remedies, we remain focused on strengthening our presence in such high-potential markets while supporting the broader agenda of improving access to affordable and quality healthcare solutions globally.”
The approval enables Venus Remedies to commercialize Ceftriaxone in Argentina through its established distribution networks, further strengthening its position in hospital-driven critical care injectable markets.
The development also reflects the company’s expanding international footprint across Latin America and reinforces India’s growing reputation as a dependable supplier of high-quality pharmaceutical solutions. Venus Remedies remains committed to regulatory excellence, sustainable growth, and improving access to life-saving therapies for healthcare providers and patients across global markets.
About Venus Remedies Ltd (venusremedies.com)
Panchkula-based Venus Remedies Ltd (NSE: VENUSREM, BSE: 526953) is among the 10 leading fixed-dosage injectable manufacturers in the world. Having a commercial presence in 90+ countries with a portfolio of 75 products spread over Europe, Australia, Africa, Asia-Pacific, Commonwealth States, the Middle East, Latin America and the Caribbean region, the company has nine globally benchmarked facilities in Panchkula, Baddi and Werne (Germany), apart from 11 overseas marketing offices. The company holds the GMP approvals from European- GMP (INFARMED), PIC/S (Malaysia & Ukraine), SAHPRA, UNICEF, TGA, INVIMA & WHO-GMP, alongside key ISO certifications for quality, environmental, and occupational health and safety management.
Central to its mission, Venus Remedies is a frontrunner in combating antimicrobial resistance (AMR) through its dedicated research division, Venus Medicine Research Centre (VMRC). The company is pivotal in developing advanced antibiotics and β-lactam/β-lactamase inhibitor combinations aimed at tackling multidrug-resistant pathogens. Its notable initiatives like GASAR provide essential data on antibiotic resistance, while the PLEA Trust fosters antibiotic stewardship. As an influential member of the AMR Industry Alliance, India AMR Innovation Hub, and Vivli AMR Registry, Venus Remedies shapes global AMR research and policy. Through strategic collaborations with academic and health organizations worldwide, the company enhances AMR surveillance and supports innovative drug development, affirming its leadership in global healthcare.
